Ketorolac (Toradol)
ketorolac tromethamine
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderately severe acute pain requiring opioid-level analgesia (parenteral) | Adults ≥17 years | Short-term monotherapy or opioid-sparing adjunct (≤5 days) | FDA Approved |
| Continuation of acute pain management (oral) | Adults ≥17 years | Continuation after IV/IM therapy only (≤5 days total) | FDA Approved |
| Moderately severe acute pain (intranasal — Sprix) | Adults ≥18 years | Short-term monotherapy or adjunct (≤5 days) | FDA Approved |
| Seasonal allergic conjunctivitis (ophthalmic 0.5%) | Adults and children | Topical ophthalmic | FDA Approved |
| Postoperative ocular inflammation after cataract surgery (ophthalmic 0.5%) | Adults | Topical ophthalmic | FDA Approved |
Ketorolac occupies a distinctive clinical niche as the only NSAID routinely used for short-term management of moderate-to-severe acute pain at potencies comparable to opioid analgesics. Its primary role is in the postoperative setting, where it serves as an opioid-sparing agent, reducing opioid consumption and associated adverse effects such as respiratory depression, ileus, and sedation. The strict five-day duration limit across all systemic formulations reflects the dose-dependent increase in gastrointestinal, renal, and cardiovascular complications seen with extended therapy. Ketorolac is expressly not intended for minor, chronic, or low-intensity pain.
Acute migraine (ED setting): IV/IM ketorolac 30 mg is widely used as a first-line parenteral option for acute migraine in the emergency department, supported by multiple randomized trials comparing it favorably with sumatriptan and opioids. Evidence quality: Moderate.
Renal colic: Ketorolac 30 mg IM/IV is used for acute ureteral colic pain, with evidence suggesting non-inferiority to parenteral opioids for initial pain relief. Evidence quality: Moderate.
Acute musculoskeletal pain/trauma: Frequently administered in emergency departments for fracture pain, sprains, and acute soft-tissue injuries. Evidence quality: Moderate.
Sickle cell vaso-occlusive crisis: Used as an adjunct analgesic to reduce opioid requirements during acute pain crises. Evidence quality: Low.
Pediatric acute pain (off-label): IV ketorolac 0.5 mg/kg (max 15 mg per dose) is used in children ≥2 years for postoperative and acute pain, though it is not FDA-approved for pediatric patients. Evidence quality: Moderate.
Dosing
Parenteral Dosing — Adults (IV and IM)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Postoperative pain — standard adult (<65 yr, ≥50 kg, normal renal function) | 30 mg IV or 60 mg IM Single-dose regimen | 30 mg IV/IM q6h | 120 mg/day | Administer IV over ≥15 seconds; combine all routes toward 5-day max IV and IM are bioequivalent |
| Postoperative pain — elderly (≥65 yr) or low body weight (<50 kg) | 15 mg IV or 30 mg IM Single-dose regimen | 15 mg IV/IM q6h | 60 mg/day | Mandatory dose reduction; higher risk of GI bleeding and renal impairment Beers criteria: use with extreme caution |
| Acute pain with moderate renal impairment (elevated serum creatinine) | 15 mg IV or 30 mg IM | 15 mg IV/IM q6h | 60 mg/day | Contraindicated in advanced renal disease or volume depletion Half-life extends to 6–19 h with renal impairment |
| Acute migraine — ED setting (off-label) | 30 mg IV or 60 mg IM | Usually single dose | 30 mg IV (single) | Often used as first-line parenteral option; pair with antiemetic if needed Reduce dose per elderly/renal rules if applicable |
| Renal colic — ED setting (off-label) | 30 mg IV or 30 mg IM | 15–30 mg q6h prn | 120 mg/day | Ensure adequate hydration; avoid in patients with pre-existing renal insufficiency |
Oral Dosing — Continuation Therapy Only
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Transition from IV/IM — standard adult (<65 yr, ≥50 kg) | 20 mg PO once First oral dose after last injection | 10 mg PO q4–6h prn | 40 mg/day | Oral ketorolac is never used as initial therapy Total combined duration (all routes) ≤5 days |
| Transition from IV/IM — elderly (≥65 yr) or <50 kg or renal impairment | 10 mg PO once | 10 mg PO q4–6h prn | 40 mg/day | Same oral max applies regardless of population No loading dose for at-risk groups |
Intranasal Dosing (Sprix)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute pain — adult ≥50 kg | 31.5 mg (1 spray per nostril) | 31.5 mg q6–8h | 126 mg/day (4 doses) | Discard bottle 24 h after first use; not an inhaled product Each spray delivers 15.75 mg |
| Acute pain — elderly, <50 kg, or renal impairment | 15.75 mg (1 spray in 1 nostril) | 15.75 mg q6–8h | 63 mg/day (4 doses) | Half the standard intranasal dose for at-risk populations |
The five-day maximum is a hard ceiling across all formulations and routes combined. Do not restart a new course immediately after completing one. For breakthrough pain during ketorolac therapy, supplement with low-dose opioids rather than increasing ketorolac dose or frequency—higher ketorolac doses above the recommended range do not provide additional analgesia but markedly increase toxicity risk. Evidence from randomized trials suggests that IV ketorolac 10 mg may produce equivalent analgesia to 30 mg, with significantly fewer adverse effects.
Pharmacology
Mechanism of Action
Ketorolac is a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), the enzymes responsible for converting arachidonic acid to prostaglandins, prostacyclin, and thromboxane A2. By suppressing prostaglandin synthesis at both peripheral and central sites, ketorolac reduces nociceptive signaling, inflammation, and pain sensitization. Its analgesic potency substantially exceeds its anti-inflammatory activity, which distinguishes it from most other NSAIDs. The S-enantiomer is the pharmacologically active form, driving virtually all analgesic and anti-inflammatory effect; the R-enantiomer contributes negligibly to efficacy. COX-1 inhibition underlies both the antiplatelet effect (through thromboxane A2 suppression) and the gastrointestinal toxicity profile (through loss of protective mucosal prostaglandins), while COX-2 inhibition at the renal level contributes to sodium retention and reduced glomerular perfusion in volume-depleted or renally compromised patients.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~100%; Tmax ~44 min (oral), ~33 min (IM); food delays but does not reduce absorption | Rapid onset by all routes; IM and IV equally bioavailable, allowing flexible route selection based on clinical setting |
| Distribution | Vd ~13 L (0.15–0.33 L/kg); protein binding 99.2% (primarily albumin); limited CNS penetration | Small distribution volume means drug remains largely intravascular; hypoalbuminemia increases free fraction and toxicity risk |
| Metabolism | Hepatic: glucuronide conjugation (major) and p-hydroxylation to inactive p-hydroxyketorolac (minor); does not induce or inhibit CYP enzymes | No significant hepatic CYP-mediated drug interactions; hepatic impairment does not substantially alter pharmacokinetics in cirrhosis |
| Elimination | t½ 5–6 h (young adults), 5–7 h (elderly), 6–19 h (renal impairment); ~92% renal (60% unchanged, 40% metabolites), ~6% fecal | Renal impairment dramatically extends half-life and doubles AUC, mandating dose reduction; age-related decline in renal function contributes to elderly risk |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 12–13% | Most common GI complaint; usually self-limiting within the 5-day treatment period; may improve with food |
| Dyspepsia | 12% | Dose-dependent; can be managed with concurrent acid suppression if needed |
| Abdominal/GI pain | 12–13% | Distinguished from GI bleeding by absence of hematemesis or melena; evaluate further if persistent or worsening |
| Headache | >10% | Marked >10% in FDA PI; often indistinguishable from postoperative headache; typically mild and self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Somnolence/Drowsiness | 4–7% | Less sedating than opioid alternatives; warn about driving during initial doses |
| Dizziness | 2–7% | Advise caution with ambulation, especially postoperatively |
| Diarrhea | 3–9% | More common with oral dosing; rarely requires treatment |
| Edema | 4% | Mild peripheral edema related to prostaglandin-mediated sodium retention; monitor weight |
| Constipation | 1–3% | Much less common than with opioid analgesia |
| Injection site pain (IM) | 2% | Can be reduced by slow injection into a large muscle (deltoid or gluteal) |
| Diaphoresis | 1% | Usually transient and self-limited |
| Increased BUN/creatinine | 2–3% | Typically reversible on discontinuation; monitor renal function in at-risk patients |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| GI bleeding/perforation | 0.4–4.5% | Any time; risk increases markedly after day 5 and with dose >60 mg/day in elderly | Discontinue immediately; urgent GI assessment; transfuse as needed; endoscopy if clinically significant |
| Acute renal failure | Rare (<1%) | Days 1–5; higher risk if volume-depleted or on concurrent nephrotoxins | Discontinue; IV fluid resuscitation; monitor electrolytes and urine output; nephrology if not resolving |
| Cardiovascular thrombotic events (MI, stroke) | Rare | Any time; risk elevated with pre-existing CV disease and prolonged use | Discontinue; emergency cardiovascular evaluation; use the lowest dose for the shortest duration |
| Anaphylaxis/Anaphylactoid reactions | Very rare | Within minutes to hours of first dose; higher risk with aspirin sensitivity | Epinephrine, airway management, emergency care; permanent discontinuation; document allergy |
| Stevens-Johnson syndrome / Toxic epidermal necrolysis | Very rare | Typically within first 2 weeks of therapy | Discontinue immediately; hospitalization; dermatology and burn center consultation |
| Operative site bleeding/hematoma | 1–1.5% | Perioperative period; within 24–72 h of surgery | Discontinue; surgical assessment; transfuse if indicated; avoid use when hemostasis is critical |
| Hepatotoxicity / Liver failure | Very rare | Variable; typically within first weeks | Discontinue; hepatology evaluation; check LFTs; monitor for signs of hepatic decompensation |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| GI intolerance (nausea, dyspepsia, abdominal pain) | ~2–3% | Most common reason; dose-related; more frequent at doses >120 mg/day |
| Dizziness/somnolence | ~1% | Usually in elderly patients or those on concurrent CNS depressants |
| Clinically significant GI bleeding | <1% | Incidence increases with age >65, doses >60 mg/day, and history of PUD |
| Renal function deterioration | <1% | Usually reversible; seen in volume-depleted or renally impaired patients |
GI bleeding risk with ketorolac is dose- and duration-dependent. A postmarketing observational study of approximately 10,000 patients demonstrated that elderly patients receiving average daily doses exceeding 60 mg had the highest rates of clinically serious GI bleeding. Minimize risk by using the lowest effective dose, adhering strictly to the 5-day limit, avoiding concurrent aspirin or other NSAIDs, and considering gastroprotective therapy (proton pump inhibitor) in patients with additional risk factors such as advanced age, corticosteroid use, or history of GI disease.
Drug Interactions
Ketorolac does not induce or inhibit hepatic CYP enzymes, so its interaction profile is primarily pharmacodynamic rather than metabolic. The most clinically significant interactions involve additive GI, renal, and bleeding risks with other agents affecting hemostasis, prostaglandin synthesis, or renal perfusion.
Monitoring
-
Renal Function
Baseline; daily if ≥3 days
Routine Serum creatinine and BUN before initiating therapy. Repeat daily in patients receiving multi-day therapy, especially if elderly, volume-depleted, or on concurrent nephrotoxins. Discontinue if significant rise in creatinine. -
Blood Pressure
Baseline; at each nursing check
Routine Monitor closely during initiation and throughout therapy. NSAIDs can elevate blood pressure and reduce efficacy of antihypertensive agents. -
GI Symptoms
Continuously
Routine Assess for epigastric pain, hematemesis, melena, and occult blood in stool. Risk increases with dose, duration, concurrent corticosteroids, anticoagulants, and history of PUD. -
Hemoglobin / CBC
Baseline; if bleeding suspected
Trigger-based Check hemoglobin before starting if multi-day therapy anticipated. Re-check promptly if signs of GI bleeding or operative site hemorrhage develop. -
Hepatic Function
If symptoms develop
Trigger-based Check ALT/AST if patient develops signs of liver dysfunction (jaundice, right upper quadrant pain, dark urine). Discontinue if abnormal LFTs persist or worsen. -
Fluid Balance
Daily
Routine Monitor fluid intake/output and daily weight. Correct hypovolemia before and during ketorolac therapy. Oliguria may indicate developing renal impairment. -
Pain Assessment
At each dose interval
Routine Use validated pain scale. If pain control inadequate, add low-dose opioid rather than increasing ketorolac above recommended dose. -
Wound/Surgical Site
Perioperatively
Trigger-based Monitor for postoperative hematoma and wound bleeding, especially in surgeries where hemostasis is critical (tonsillectomy, cardiac, orthopedic). Ketorolac inhibits platelet function.
Contraindications & Cautions
Absolute Contraindications
- Active peptic ulcer disease, recent GI bleeding, or perforation — ketorolac can cause fatal GI hemorrhage even during short-term use
- History of peptic ulcer disease or GI bleeding — risk of recurrent hemorrhage is substantially elevated
- Advanced renal impairment or volume depletion — prostaglandin-dependent renal perfusion is critical in these patients
- Known hypersensitivity to ketorolac, aspirin, or other NSAIDs — cross-reactivity can trigger bronchospasm or anaphylaxis
- Aspirin-sensitive asthma (aspirin triad) — risk of severe bronchospasm and anaphylactoid reactions
- Perioperative use in CABG surgery — FDA contraindication due to increased cardiovascular thrombotic events
- Prophylactic analgesic use before any major surgery — risk of perioperative bleeding from platelet inhibition
- Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis
- Concurrent use with other NSAIDs, aspirin, probenecid, or pentoxifylline
- Labor and delivery — may inhibit uterine contractions and adversely affect fetal circulation
- Neuraxial (epidural/intrathecal) administration — injection formulation contains alcohol
Relative Contraindications (Specialist Input Recommended)
- Moderate renal impairment (elevated serum creatinine) — requires mandatory dose reduction to ≤60 mg/day parenterally; monitor renal function closely
- Concurrent anticoagulant therapy (warfarin, heparin, DOACs) — substantially elevated bleeding risk; use only if no alternative and with close monitoring
- Concurrent corticosteroid therapy — compounded GI bleeding risk; consider gastroprotection
- Heart failure or significant fluid retention — NSAID-mediated sodium and water retention can precipitate decompensation
- Elderly patients (≥65 years) — AGS Beers criteria classifies ketorolac as potentially inappropriate due to elevated risk of GI, renal, and CV toxicity
Use with Caution
- Hepatic impairment — evidence in cirrhosis suggests dosage adjustment may not be needed, but monitor LFTs
- Pre-existing asthma without known NSAID sensitivity — observe for bronchospasm
- Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) — NSAIDs may exacerbate symptoms
- Concurrent SSRI/SNRI therapy — increased bleeding risk; consider gastroprotection
- Patients on ACE inhibitors, ARBs, or diuretics — monitor renal function and blood pressure
- Breastfeeding — ketorolac is excreted in breast milk in small amounts; assess risk-benefit
Duration limit: The total combined duration of ketorolac therapy across all routes (IV, IM, oral, intranasal) must not exceed five days due to increased risk of serious adverse events including gastrointestinal bleeding, renal failure, and cardiovascular thrombotic events.
GI risk: Ketorolac can cause peptic ulcers, gastrointestinal bleeding, and perforation, which can be fatal. These events may occur without warning at any time during therapy.
Renal risk: Contraindicated in patients with advanced renal disease or those at risk for renal failure due to volume depletion.
Bleeding risk: Ketorolac inhibits platelet function and is contraindicated in patients with hemorrhagic diathesis, suspected cerebrovascular bleeding, or incomplete hemostasis, and in those at high risk of bleeding.
Cardiovascular risk: NSAIDs cause increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. Contraindicated in the perioperative setting of CABG surgery.
Pediatric use: Ketorolac is not indicated for use in pediatric patients (injection PI).
Not for minor or chronic pain: Ketorolac is indicated only for moderately severe acute pain requiring opioid-level analgesia. Increasing the dose beyond recommendations does not improve efficacy but increases risk.
Patient Counselling
Purpose of Therapy
Ketorolac is a powerful anti-inflammatory pain reliever used for a short time (never more than 5 days total) to control moderate-to-severe pain, usually after surgery or an acute injury. It works differently from opioid painkillers and does not cause the same kind of drowsiness, constipation, or risk of dependence. You may receive it first as an injection and then as tablets to continue at home, but the total treatment must not exceed five days.
How to Take
Take tablets exactly as prescribed, at regular intervals (usually every 4–6 hours), with or without food. If you experience stomach upset, taking it with food or milk may help. Do not take more than 40 mg in any 24-hour period. Do not take any other NSAID painkillers (such as ibuprofen, naproxen, or aspirin) while using ketorolac. Count the day of your first injection as day 1 and stop all ketorolac on day 5.
Sources
- Ketorolac Tromethamine Injection, USP — FDA-Approved Prescribing Information (Revised 2014). accessdata.fda.gov Primary reference for parenteral dosing, contraindications, boxed warning, and adverse reaction rates from pivotal trials.
- Toradol Oral (ketorolac tromethamine tablets) — FDA-Approved Prescribing Information (Revised 2013). accessdata.fda.gov Source for oral pharmacokinetic data, oral dosing continuation therapy guidelines, and the PK comparison table.
- Sprix (ketorolac tromethamine) Nasal Spray — FDA-Approved Prescribing Information (Revised 2018). accessdata.fda.gov Reference for intranasal formulation dosing, intranasal-specific adverse effects, and administration instructions.
- Motov S, Yasavolian M, Likourezos A, et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med. 2017;70(2):177–184. doi:10.1016/j.annemergmed.2016.10.014 RCT demonstrating equivalent analgesia at 10 mg, 15 mg, and 30 mg IV doses, supporting use of lower doses to reduce adverse effects.
- Taggart E, Doran S, Kokotillo A, et al. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013;53(2):277–287. doi:10.1111/head.12009 Systematic review supporting ketorolac’s efficacy for acute migraine, relevant to its off-label use in emergency departments.
- Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA. 1996;275(5):376–382. doi:10.1001/jama.1996.03530290046036 Large postmarketing study (~10,000 patients) establishing dose-dependent GI bleeding rates that informed current dosing restrictions.
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372 Lists ketorolac among potentially inappropriate medications in older adults due to risk of GI bleeding, renal failure, and cardiovascular events.
- Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from APS, ASRA, and ASA. J Pain. 2016;17(2):131–157. doi:10.1016/j.jpain.2015.12.008 Multidisciplinary guideline recommending NSAIDs including ketorolac as part of multimodal postoperative pain management to reduce opioid requirements.
- Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6 Pt 2):33S–39S. doi:10.1002/j.1875-9114.1990.tb03578.x Foundational PK study establishing complete bioavailability, protein binding, and metabolic pathway data for ketorolac.
- Buckley MMT, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs. 1990;39(1):86–109. doi:10.2165/00003495-199039010-00008 Comprehensive early drug review covering pharmacology, clinical efficacy data, and adverse effect profile from single- and multiple-dose studies.
- Jung D, Mroszczak EJ, Bynum L. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol. 1988;35(4):423–425. doi:10.1007/BF00561376 Cross-over PK study in healthy volunteers establishing terminal half-life, clearance, volume of distribution, and complete oral bioavailability.
- Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet. 1992;23(6):415–427. doi:10.2165/00003088-199223060-00003 Review of ketorolac PK covering stereoselective disposition, special populations (elderly, renal impairment), and breast milk excretion.
- Gillis JC, Brogden RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53(1):139–188. doi:10.2165/00003495-199753010-00012 Updated review including revised dosing guidelines and safety data that informed the reduction in recommended maximum daily doses.
- Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–1817. doi:10.1056/NEJMoa003199 Key study on NSAID-aspirin platelet interaction relevant to understanding ketorolac’s antiplatelet mechanism and concurrent aspirin contraindication.